surufatinib
Showing 1 - 25 of 39
Surufatinib in G3 Neuroendocrine Tumors
Not yet recruiting
- Neuroendocrine Tumor Grade 3
- Surufatinib
- (no location specified)
Aug 2, 2023
Differentiated Thyroid Cancer Trial in Shanghai (surufatinib)
Recruiting
- Differentiated Thyroid Cancer
- surufatinib
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 9, 2023
Soft Tissue Sarcoma Adult Trial (Surufatinib)
Not yet recruiting
- Soft Tissue Sarcoma Adult
- Surufatinib
- (no location specified)
Oct 29, 2023
Renal Impairment Trial in Tustin, Orlando (Surufatinib)
Completed
- Renal Impairment
- Surufatinib
-
Tustin, California
- +1 more
Nov 2, 2022
Advanced NSCLC Trial in Guangzhou (Surufatinib, Surufatinib Plus Vinorelbine)
Recruiting
- Advanced Non-Small Cell Lung Cancer
- Surufatinib
- Surufatinib Plus Vinorelbine
-
Guangzhou, Guangdong, ChinaAffiliated Cancer Hospital and Institute of Guangzhou Medical Un
Aug 18, 2022
Hepatic Impairment Trial in Tustin, Orlando (Surufatinib)
Completed
- Hepatic Impairment
- Surufatinib
-
Tustin, California
- +1 more
Aug 29, 2022
Ovarian Cancer Trial in Hefei (Pamiparib, Surufatinib)
Recruiting
- Ovarian Cancer
- Pamiparib
- Surufatinib
-
Hefei, Anhui, ChinaAnhui Cancer Hospital
Dec 6, 2022
Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Surufatinib
- Irinotecan
- (no location specified)
Nov 27, 2022
Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)
Not yet recruiting
- Metastatic Triple-negative Breast Cancer
- Surufatinib
- Tislelizumab
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023
Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)
Not yet recruiting
- Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- surufatinib
- +3 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Apr 16, 2023
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Surufatinib
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 20, 2023
Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)
Recruiting
- Neuroendocrine Tumor Grade 3
- +2 more
- Surufatinib
- Sintilimab
-
Tianjin, Tianjin, ChinaRui Liu
Nov 17, 2022
Sarcoma Trial in Guangzhou (Surufatinib)
Recruiting
- Sarcoma
- Surufatinib
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Univerisity
May 5, 2022
Pancreatic Tumors Trial in Guangzhou (Surufatinib, TAS-102)
Not yet recruiting
- Pancreatic Neoplasms
- Surufatinib
- TAS-102
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Jul 28, 2022
Pancreatic Tumors Trial in Guangzhou (Surufatinib, Sintilimab, AG)
Not yet recruiting
- Pancreatic Neoplasms
- Surufatinib
- +2 more
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Jul 28, 2022
Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)
Not yet recruiting
- Extensive-Stage Small Cell Lung Cancer
- Surufatinib
- Anti-PD-1/L1
-
Beijing, ChinaChinese PLA General Hospital
Aug 18, 2022
Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic Trial in Guangzhou (Surufatinib)
Recruiting
- Adenocarcinoma of Small Intestine
- +2 more
- Surufatinib
-
Guangzhou, Guangdong, ChinaThe Sixth Affiliated Hospital of Sun Yat-sen University
Jul 22, 2022
Neuroendocrine Tumors Trial in United States (Surufatinib)
No longer available
- Neuroendocrine Tumors
- Surufatinib
-
Denver, Colorado
- +10 more
Oct 28, 2022
Tumors Trial in Italy, United States (surufatinib)
Completed
- Tumors
- surufatinib
-
Los Angeles, California
- +11 more
Jan 11, 2023
Hepatocellular Carcinoma Trial in Nanjing (Surufatinib)
Recruiting
- Hepatocellular Carcinoma
- Surufatinib
-
Nanjing, Jiangsu, ChinaNanjing Drum tower hospital
Apr 6, 2022
Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)
Recruiting
- Colorectal Cancer
- Surufatinib
- +2 more
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Feb 26, 2022
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival Trial in Wuhan (Surufatinib)
Recruiting
- Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
- Surufatinib
-
Wuhan, Hubei, ChinaZhongnan Hopital of Wuhan University
Mar 8, 2022